How many more days of Progynova (estradiol) is needed for a woman of reproductive age on day 9 of her Frozen Embryo Transfer (FET) cycle with an endometrial thickness of 7.2mm, currently taking 12mg of Progynova as part of her Hormone Replacement Therapy (HRT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Duration of Progynova (Estradiol) for HRT-FET Protocol

Continue Progynova for approximately 5-7 more days until endometrial thickness reaches ≥8mm, then initiate progesterone supplementation. The current endometrial thickness of 7.2mm on day 9 is approaching but has not yet reached the optimal threshold for progesterone initiation in a hormone replacement therapy frozen embryo transfer (HRT-FET) cycle.

Endometrial Preparation Timeline

Current Status Assessment

  • Day 9 with 7.2mm endometrium requires continued estrogen priming before progesterone initiation 1
  • The target endometrial thickness is ≥8mm, with optimal outcomes seen at thicknesses >7mm 1
  • Clinical pregnancy rates increase progressively with endometrial thickening in HRT-FET cycles 1

Estrogen Continuation Protocol

  • Continue 12mg Progynova daily until endometrial thickness reaches 8-10mm 1
  • Typical duration of estrogen priming in HRT-FET protocols ranges from 12-18 days total before progesterone initiation 2, 3
  • Monitor endometrial thickness every 2-3 days after day 10 to determine optimal timing for progesterone start 1

Progesterone Initiation Timing

  • Begin progesterone supplementation once endometrial thickness is ≥8mm, typically occurring around days 14-16 of the cycle 2, 3
  • The timing of progesterone start is critical for embryo-endometrial synchronization in FET cycles 3
  • For a day 5 blastocyst transfer, progesterone should be administered for 5 days before transfer; for a day 3 embryo, 3 days of progesterone exposure is needed 2, 3

Progesterone Supplementation Regimen (Once Initiated)

Recommended Progesterone Protocol

  • Vaginal micronized progesterone 200mg three times daily (600mg total) is the preferred first-line regimen for HRT-FET cycles due to higher intrauterine concentrations via first uterine pass effect 2, 4
  • Alternative: Intramuscular progesterone may provide superior outcomes in some studies, with one RCT showing improved clinical pregnancy rates (RR 1.46,95% CI 1.21-1.76) and live birth rates (RR 1.62,95% CI 1.28-2.05) compared to vaginal administration 4
  • Target serum progesterone concentration on day 16 of the cycle (approximately 5 days after progesterone initiation) should be >50 nmol/L (>15.8 ng/mL) for optimal outcomes 5

Monitoring and Adjustment

  • Measure serum progesterone concentration 5 days after initiating progesterone to ensure adequate levels 5
  • Live birth rates are significantly higher with day 16 progesterone >50 nmol/L (26.4% vs 11.3% for <50 nmol/L; adjusted OR 3.14,95% CI 2.21-4.48) 5
  • Pregnancy loss rates are lower with adequate progesterone levels (14.3% vs 32.6% for ≤50 nmol/L; adjusted OR 0.26,95% CI 0.12-0.58) 5

Critical Pitfalls to Avoid

Premature Progesterone Initiation

  • Do not start progesterone with endometrial thickness <7mm, as this is associated with significantly worse outcomes 1
  • Starting progesterone too early disrupts the window of implantation and reduces embryo-endometrial synchronization 2, 3

Inadequate Progesterone Dosing

  • A significant proportion of patients do not reach adequate progesterone concentrations regardless of administration route, necessitating individualized monitoring 2
  • There is positive correlation between live births and both the number of progesterone doses per day (r = 0.119, P = 0.026) and day 16 progesterone concentrations (r = 0.128, P = 0.011) 5

Thin Endometrium Management

  • If endometrial thickness remains <7mm after 14-16 days of Progynova, consider adding vaginal Femoston (estradiol/dydrogesterone combination) to improve endometrial receptivity 1
  • Patients with thin endometrium who received combined Progynova plus Femoston showed improved clinical pregnancy rates compared to historical controls with Progynova alone 1

Estrogen Continuation During Progesterone Phase

  • Continue Progynova at the same dose (12mg daily) throughout progesterone supplementation and after embryo transfer 2, 3
  • Estrogen support should be maintained until at least 10-12 weeks of gestation if pregnancy is achieved 2
  • There is no consensus on optimal estradiol levels, but monitoring is less critical than ensuring adequate progesterone concentrations 2, 1

References

3
Research

Progesterone supplementation in the frozen embryo transfer cycle.

Current opinion in obstetrics & gynecology, 2015

5
Research

Progesterone concentrations and dosage with frozen embryo transfers - What's best?

The Australian & New Zealand journal of obstetrics & gynaecology, 2018

Related Questions

What are the implications and next steps for a patient who achieves an endometrial thickness of 8mm on Progynova (Estradiol) 2mg, and what is the minimum time of exposure for Progynova in Frozen Embryo Transfer (FET) cycles?
What are the typical hormonal changes after 10 days of a successful Frozen Embryo Transfer (FET)?
In a fresh embryo transfer, is Progynova (estradiol) given or is progesterone directly started after egg pickup?
What are the optimal levels of progesterone and estrogen prior to frozen embryo transfer (FET)?
How should I proceed with a patient on Progynova (estradiol valerate) 6 mg for a Frozen Embryo Transfer (FET) cycle, currently on day 8 with an endometrial thickness of 8.5 mm and a triple line pattern?
What is the approach to diagnosing secondary pulmonary tuberculosis (PTB) in a patient with a history of tuberculosis or other respiratory conditions, considering their age, immune status, and previous treatments?
What is the differential diagnosis for a patient presenting with bilateral leg weakness, considering potential underlying conditions such as spinal cord compression, acute stroke, or Guillain-Barré syndrome?
Is trypsin (enzyme) chymotrypsin (enzyme) safe for use in a diabetic patient, especially those with a history of pancreatic disease?
What is the ASIA (American Spinal Injury Association) grade in a patient with a spinal cord injury at or above the T6 level?
Can emotional stress cause leukocytosis in a healthy adult or one with a history of anxiety or depression?
I'm experiencing testicular ptosis (drooping testicles) and potential testicular atrophy (shrinking testicles), what could be causing this at my age?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.